Development of a novel Z-scheme CoxNi1-xTiO3/CdS (x = 0.5) photocatalyst for the efficient degradation of organic pollutants via a visible-light-driven photocatalytic process

Herein, for the first time, we reported the synthesis of a novel Z-scheme CoxNi1-xTiO3/CdS (x = 0.5) heterojunction photocatalyst and the investigation of its visible-light-driven photocatalytic performance toward degradation of methylene blue (MB). The developed photocatalyst was structurally characterized by applying X-Ray diffraction analysis (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), Brunauer-Emmett-Teller (BET), differential reflectance spectroscopy (DRS), and photoluminescence (PL) techniques. The results indicated the formation of a highly porous structure with improved visible light adsorption capacity, favorable for the catalytic activity. At an optimum condition of 10 mg/L of MB and 300 mg/L of catalyst, the ternary photocatalyst demonstrated a MB removal efficiency of 99 % after 75 min of the treatment process. The radical trapping experiments unveiled that hydroxyl and superoxide radicals were two main reactive species formed under visible light, while the valance holes possessed an insignificant role. The synergetic impact of the CoxNi1-xTiO3 (x = 0.5) and CdS on the photodegradation of MB over the as-prepared CoxNi1-xTiO3/CdS (x = 0.5) photocatalyst through Z-scheme photocatalysis was indicated by the results of the mechanism studies. The percentage impact of the treatment time, MB concentration, the ratio of CoxNi1-xTiO3/CdS (x = 0.5), and the dosage of catalyst using analysis of the CCD modeling was obtained as 47.04, 16.67, 7.22 and 0.87 %, respectively. Furthermore, the as-synthesized photocatalyst possessed high recyclability and photostability with only a 3 % decline in activity after four repetitive cycles.

Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS: In vitro and in silico metabolic study

Spebrutinib is a new Bruton tyrosine kinase inhibitor developed by Avila Therapeutics and Celgene. Spebrutinib (SPB) is currently in phase Ib clinical trials for the treatment of lymphoma in the United States. Preliminary in-silico studies were first performed to predict susceptible sites of metabolism, reactivity pathways and structural alerts for toxicities by StarDrop WhichP450™ module, Xenosite web predictor tool and DEREK software; respectively. SPB metabolites and adducts were characterized in vitro from rat liver microsomes (RLM) using LC-MS/MS. Formation of reactive intermediates was investigated using potassium cyanide (KCN), glutathione (GSH) and methoxylamine as trapping nucleophiles for the unstable and reactive iminium, iminoquinone and aldehyde intermediates, respectively, with the aim to produce stable adducts that can be detected and characterized using mass spectrometry. Fourteen phase I metabolites, four cyanide adducts, six GSH adducts and three methoxylamine adducts of SPB were identified and characterized. The proposed metabolic pathways involved in generation of phase I metabolites of SPB are oxidation, hydroxylation, o-dealkylation, epoxidation, defluorination and reduction. Several in vitro reactive intermediates were identified and characterized, the formation of which can aid in explaining the adverse drug reactions of SPB. Several iminium, 2-iminopyrimidin-5(2H)-one and aldehyde intermediates of SPB were revealed. Acrylamide is identified as a structural alert for toxicity by DEREK report and was found to be involved in the formation of several glycidamide and aldehyde reactive intermediates.